Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 19, 2026
TickeronGET DAILY SIGNALS
Why Is Cibus, Inc. (CBUS) Stock Down -10.95% Today?

Why Is Cibus, Inc. (CBUS) Stock Down -10.95% Today?

Key Takeaways

  • Cibus, Inc. (CBUS) shares fell 10.95% to $1.22 in midday trading, a decline of $0.15 from Wednesday's $1.37 close.
  • The dominant driver remains the unresolved funding overhang flagged with third-quarter results: cash of $10.7 million and a runway management says reaches only into early first quarter of 2027.
  • A secondary driver is profit-taking after an 18% two-session rebound on November 16–17 that lacked a confirmed fundamental trigger.
  • An analyst price target cut to $9 from $16 and a rice royalty timeline pushed out to 2028 have kept the post-earnings narrative bearish.
  • The move is idiosyncratic rather than sector-wide, and it unwinds the entire mid-November bounce back to the November 16 closing level of $1.20.
  • News Significance Score: 44/100 — Moderate fundamental news, with a move roughly three times the stock's normal daily swing.
  • Traders are watching for a financing announcement, a definitive Interoc commercialization agreement, and first-quarter 2027 Ecuador trial results.
  • Deeper detail on Price Targets, Earnings, and Forecast is available on the dedicated Cibus pages.
  • Explore Trending AI Robots to see which automated strategies are performing best in the current market.

Cibus Shares Give Back the November Rebound

Cibus, Inc. (CBUS) is a San Diego–based agricultural biotechnology company that makes precise edits to a seed company's own elite crop varieties — with no foreign DNA added — and licenses those improved traits back to the customer for royalties. Its pipeline centres on herbicide-tolerant rice, pod shatter reduction in canola and oilseed rape, and a biofragrance ingredient business built on yeast fermentation.

In midday trading Thursday, the stock changed hands at $1.22, down $0.15, or 10.95%, from the prior session's close of $1.37. The direction is unambiguously lower, and the move erases the gains from a sharp two-day advance that lifted shares from $1.20 on November 16 to $1.39 on November 17. No company-specific announcement explained the session's decline; the drivers were a still-unresolved funding question and the unwind of speculative positioning built during that rally.

Cash Runway Remains the Central Bear Case

The third quarter, reported after the close on November 12, delivered revenue of $0.8 million against expectations near $2.0 million, and a per-share loss of $0.29 versus a consensus loss of about $0.27. More consequentially, cash and equivalents stood at $10.7 million at September 30, down from $30.3 million at the start of the year, with management stating that current resources fund operations only into early first quarter of 2027 absent new capital.

Cost discipline has improved — research and development expense fell to $7.9 million from $10.8 million, and nine-month operating cash use dropped roughly 19% — but the royalty liability now stands at $263.4 million and stockholders' equity has turned negative. For a pre-revenue-royalty company trading under $1.50, the timing and terms of the next raise carry disproportionate weight, and the equity historically sells off when that overhang returns to the foreground.

A Speculative Rally Loses Its Bid

The November 17 session, which carried the stock 15.8% higher on roughly 472,000 shares — several times the recent daily turnover of roughly 70,000 to 80,000 shares — was not accompanied by a company release or filing. Without a durable catalyst, that kind of volume spike in a sub-$2 micro-cap tends to be short-lived, and the subsequent two sessions have retraced the entire advance. That pattern is consistent with momentum-driven buying reversing into profit-taking rather than with a fresh deterioration in fundamentals.

Analyst Reset Reinforces the Bearish Tilt

Sell-side sentiment reset lower after the quarter. One covering firm cut its price target to $9 from $16 while maintaining a Buy rating, noting that the crop-trait royalty ramp is now a 2028 event and that continued cash burn adds financing risk. A target cut of that magnitude does not by itself move a stock on any given day, but it reframes the timeline investors are underwriting and removes the expectation of near-term royalty revenue from Latin America.

Market Context and Trading Activity

The decline is company-specific rather than sector-driven. Cibus trades as a thin, heavily retail-influenced micro-cap with a market capitalisation of roughly $93 million on about 77 million shares, and its daily swings are driven far more by liquidity and positioning than by agricultural biotechnology peers. Turnover on Thursday was light relative to the November 17 spike, which suggests limited buying interest rather than aggressive institutional selling.

Technically, the stock failed to hold above the $1.35–$1.40 area that capped it in late November and has slipped back to the $1.20 level that marked the base of the mid-month rally. The November 13 low of $1.02 remains the nearest reference point on the downside, while the $1.50–$1.52 intraday high from November 17 is the immediate resistance level.

News Significance Score

The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. Cibus scores 44 out of 100.

The verified fundamental news is moderate but material for a company this size: a 41% revenue miss, a cash position that funds only about one more quarter, and a halved price target. The price move was roughly 3.3 times the stock's typical absolute daily change of 3.3% over the past 60 sessions, and only one of those sessions produced a move this large — the 15.8% gain on November 17. Strong-but-not-transformative news combined with an unusual move produces the mid-range score.

What Comes Next for CBUS

The most immediate variable is financing. Management has acknowledged an acute need for near-term capital, so the size, structure, and pricing of any raise will shape the next leg of trading. Beyond that, investors await a definitive commercialization agreement with Interoc covering herbicide-tolerant rice, with field results from Interoc's own varieties in Ecuador expected in the first quarter of 2027, and a regulatory dossier for Brazil in preparation.

On the ingredients side, the partner has approved the first two biofragrance products and manufacturing scale-up has begun, but purchase orders depend on formulation wins that have not yet materialised. Fourth-quarter and full-year 2026 results, expected in March, will be scrutinised for cash burn against the roughly $35 million annualised exit target. Risks include further equity dilution, commercial launch slippage beyond 2028, and pending regulatory approvals in Latin America and Europe.

Trending AI Robots

Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in the curated Trending AI Robots section. Bots vary widely by strategy, timeframe, performance metrics, and traded symbols, so the selection is designed to surface the strategies currently working rather than the ones that worked last quarter. For readers tracking volatile micro-caps like this one, it is a practical starting point for comparing systematic approaches.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CBUS

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


CBUS's RSI Oscillator ascends from oversold territory

The RSI Indicator for CBUS moved out of oversold territory on November 04, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 39 similar instances when the indicator left oversold territory. In 37 of the 39 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 62 cases where CBUS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.

The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on CBUS as a result. In 71 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

The Moving Average Convergence Divergence (MACD) for CBUS just turned positive on November 16, 2026. Looking at past instances where CBUS's MACD turned positive, the stock continued to rise in 39 of 44 cases over the following month. The odds of a continued upward trend are 89%.

Following a +23.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where CBUS advanced for three days, in 206 of 245 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CBUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

CBUS broke above its upper Bollinger Band on November 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CBUS entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. CBUS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.093) is normal, around the industry mean (3.596). P/E Ratio (-0.781) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (21.692) is also within normal values, averaging (443.347).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CBUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -9%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -25%. VIVS experienced the highest price growth at 111%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 84%. For the same stocks of the Industry, the average monthly volume growth was 101% and the average quarterly volume growth was 38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
6455 Nancy Ridge Drive
Phone
+1 858 450-0008
Employees
118
Web
https://www.cibus.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.